Sulfonylureas are an older class of type 2 diabetes therapy but remain the most commonly prescribed antidiabetic drug after metformin.
Patients taking metformin for type 2 diabetes (T2D) who switch to a sulfonylurea are at increased cardiovascular (CV) risk, according to findings reported Wednesday. The long-term study found that the links to heart attacks and death were driven by trading metformin for a sulfonylurea, not by adding sulfonylureas to metformin.
Clinical guidelines typically call for patients newly diagnosed with T2D to start with metformin, and to add therapies if they are unable to achieve glycemic control, or change drugs if they cannot tolerate metformin. Sulfonylureas were introduced in the 1950s, and a popular third-generation therapy, glimepiride, arrived in 1995.
In recent years, new classes including dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium glucose co-transporter-2 (SGLT2) inhibitors, have arrived, including several that have been shown to offer cardioprotective benefits. As the researchers noted, however, sulfonylureas remain the commonly prescribed treatment for T2D if patients cannot sufficiently lower their glycated hemoglobin (A1C) on metformin alone.
Researchers led by Antonios Douros, MD, PhD, of the Lady Davis Institute at Jewish General Hospital in Montreal, Canada, matched records from healthcare databases in the United Kingdom with diagnostic codes to examine what happened to 77,138 people with T2D who started taking metformin between 1993 and 2013. About one-third (25,699 people) either added or switched to a sulfonylurea.
To see the effect on all-cause mortality, the researchers examined results for 23,592 patients who added or switched to sulfonylureas, matched with 23,592 who stayed on metformin alone. Matched cohorts of a similar size also examined the effect of adding or switching sulfonylureas on hospital admission for myocardial infarction, hospital admission for ischemic stroke, CV death, and severe hypoglycemia.
Results showed:
“In line with current recommendations on the treatment of type 2 diabetes, continuing metformin when introducing sulfonylureas is safer than switching,” the authors concluded.
Reference
Douros A, Dell’Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second-line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycemic events: population based cohort. BMJ. 2018;362:k2693. doi:10.1136/bmjk2693.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More